Probiotics Improve Constipation
Condition(s) studied
Investigational drug(s) / intervention(s)
Probitics: The intervention period of this study will last for 8 weeks (56 days), during which each participant will attend three study visits scheduled at baseline (Week 0), Week 1, Week 2, Week 4, and Week 8.
Placebo: The intervention period of this study will last for 8 weeks (56 days), during which each participant will attend three study visits scheduled at baseline (Week 0), Week 1, Week 2, Week 4, and Week 8.
Study summary
This study is a randomized, double-blind, placebo-controlled trial in which adult subjects with constipation are randomly assigned to either a probiotic group or a placebo group for an 8-week intervention. Through blood and fecal sample analyses combined with multidimensional questionnaire assessments, the study aims to systematically evaluate the efficacy of probiotics in improving gastrointestinal function, immune status, and mental health in patients with constipation.
Eligibility
Primary outcome measure(s)
- Improvement of constipation symptoms — Baseline, Week 1, Week 2, Week 4, Week 8
Improvement in constipation was assessed using the Bristol Stool Characteristics Scale (BSFS), primarily observing the shift in stool type from type 1-2 (hard stool/constipation) to type 3-4 (normal/ideal soft stool). - Change in Spontaneous Bowel Movement (SBM) Frequency — Baseline, Week 1, Week 2, Week 4, Week 8
Change from baseline in number of spontaneous bowel movements. Spontaneous bowel movements are defined as bowel movements occurring without the use of laxatives, enemas, or suppositories within the previous 24 hours.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Suzhou Ninth People's Hospital | Suzhou | Jiangsu | Recruiting |
More Wecare Probiotics Co., Ltd. trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07765004 on ClinicalTrials.gov ↗ ← All trials in China